In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Condition(s)
Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Drug Pill Drug
Cyclophosphamide-based chemotherapy

Genetic Double Helix Genetic
Genetically Modified T cells
Trial Summary & Details
Ages: Child, Adult, Older Adult
Condition: Acute Lymphocytic Leukemia, Lymphoma

The purpose of this study is to test the safety of giving the patient special cells from a donor called “Modified T-cells”. The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want to find out what effects these T-cells have on the patient and the disease.

Status
Recruiting
Location(s)
Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY

Sponsor/Collaborators:
Memorial Sloan Kettering Cancer Center (MSKCC)
Contact
Kevin Curran, MD
212-639-5836